175 - An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Second Generation Oral Bivalent Vaccine Candidate

Presenting Author(s)

• 

  Nicholas J. Bennett, MBBChir, PhD

  Medical Director
  Vaxart Inc
  PONTE VEDRA, Florida, United States

  Slides

Co-Author(s)

• 

  Becca A. Flitter, PhD, MPH

  Senior Scientist
  Vaxart Inc
  South San Francisco, California, United States
• CL

  Colin A. Lester, n/a

  Research Associate III
  Vaxart, Inc.
  South San Francisco, California, United States
• ND

  Nick P. D'Amato, MSc

  Director of Clinical Operations
  Vaxart Inc.
  South San Francisco, California, United States
• MA

  Maria D. Apkarian, BA

  Vice President Clinical Operations
  Vaxart Inc.
  Phoenix, Arizona, United States
• ST

  Sean N. Tucker, PhD

  CSO, VP of Research
  Vaxart
  South San Francisco, California, United States
• JC

  James F. Cummings, MD

  Chief Medical Officer
  VAXART
  South San Francisco, California, United States